University of Pennsylvania
Wynnewood, PA, United States
Dr. Victoria Werth is a Professor of Dermatology and Medicine at the University of Pennsylvania School of Medicine and Chief of the Division of Dermatology at the Philadelphia Veterans Administration Hospital. Dr. Werth earned her medical degree from Johns Hopkins University School of Medicine in Baltimore, Maryland. She completed a residency in internal medicine at Northwestern Memorial Hospital in Chicago, Illinois, and dermatology residency and immunodermatology fellowship at New York University School of Medicine in New York. She joined the faculty at Penn in 1989 and has developed an internationally recognized program in autoimmune skin diseases.
Applying the Guideline to Treat Cutaneous Lupus
Sunday, October 26, 2025
9:30 AM – 10:00 AM Central Time
Disclosure(s): AbbVie: Consultant (Terminated, March 17, 2022); AbbVie/Abbott: Consultant (Ongoing); Amgen: Consultant (Ongoing), Grant/Research Support (Ongoing); Anaptysbio: Consultant (Ongoing); argenx: Consultant (Ongoing), Grant/Research Support (Ongoing), Grant/Research Support (Ongoing); AstraZeneca: Consultant (Ongoing); Biogen: Consultant (Ongoing), Grant/Research Support (Ongoing); Bristol Myers Squibb: Consultant (Ongoing); Bristol Myers Squibb (BMS): Consultant (Ongoing); Celgene: Consultant (Terminated, October 21, 2021), Grant/Research Support (Terminated, October 21, 2021); Corbus: Grant/Research Support (Terminated, January 11, 2021); CSL Behring: Consultant (Ongoing), Grant/Research Support (Ongoing), Grant/Research Support (Ongoing); Eli Lilly: Consultant (Ongoing); EMD Serono: Consultant (Ongoing); Galderma: Consultant (Ongoing); Genentech: Consultant (Ongoing), Grant/Research Support (Ongoing), Grant/Research Support (Ongoing); Gilead: Consultant (Ongoing), Consultant (Ongoing), Grant/Research Support (Ongoing); GlaxoSmithKline: Consultant (Ongoing); GlaxoSmithKline (GSK): Consultant (Ongoing); Horizon Therapeutics: Consultant (Ongoing), Grant/Research Support (Ongoing), Grant/Research Support (Ongoing); Idera: Consultant (Ongoing); Incyte: Consultant (Ongoing); Janssen: Consultant (Ongoing); Kyowa Kirin: Consultant (Ongoing); Lilly: Consultant (Ongoing); MedImmune: Consultant (Ongoing); Medscape: Consultant (Ongoing); Merck: Consultant (Ongoing); Merck/MSD: Consultant (Ongoing); Nektar: Consultant (Ongoing); Novartis: Consultant (Ongoing); Octapharma: Consultant (Ongoing); Pfizer: Consultant (Ongoing), Grant/Research Support (Ongoing); Principia: Consultant (Ongoing); Regeneron: Consultant (Ongoing), Grant/Research Support (Ongoing), Grant/Research Support (Ongoing); Resolve: Consultant (Ongoing); Rome Pharmaceuticals: Consultant (Ongoing); Rome Therapeutics: Consultant (Ongoing), Grant/Research Support (Ongoing); Sanofi: Consultant (Ongoing); Syntimmune: Grant/Research Support (Terminated, December 31, 2021); Ventus: Grant/Research Support (Ongoing); Viela: Consultant (Terminated, May 6, 2022), Consultant (Terminated, May 6, 2022), Grant/Research Support (Terminated, May 6, 2022); Xencor: Consultant (Ongoing)
